Without the advance screening of biomarkers in each NSCLC individual, this small subset would not be successfully discovered, and the common EGFR tyrosine kinase inhibitors would have been prescribed to all NSCLC patients albeit the limited efficacy in patients with EML4-ALK alteration. The gene discussed is ALK; the disease is non-small cell lung carcinoma.